Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance. Michele also speaks to how Recce® 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis.
@ReccePharma
#antibioticresistance #syntheticantibodies #infections #superbugs #sepsis
Recce.com.au
Download the transcript here.
Empowered Patient Podcast